Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT-112 in Relapsed or Refractory Multiple Myeloma
NCT03288480Phase 1Completed
- Sponsor
- Promontory Therapeutics
- Start
- Dec 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Imifoplatin in multiple myeloma (MM), sponsored by Promontory Therapeutics. Primary endpoint: Recommended dose (RD) of PT-112 at 18 months. Started Dec 2017; status: completed.
02
Drugs
Imifoplatin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03288480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03288480.